{"transactions":[{"id":672952,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true}}],"security":"Restricted Stock Unit","published_at":"2026-08-28T16:01:41.000Z","date":"2026-08-26","kind":"exercise","planned":false,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001437749-26-029175","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774926029175/rdgdoc.xml","form_type":"4"}},{"id":672951,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true}}],"security":"ordinary shares","published_at":"2026-08-28T16:01:41.000Z","date":"2026-08-26","kind":"exercise","planned":false,"acquired":true,"shares":2000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"}],"balance_after":8000,"source":{"system":"sec-edgar","filing":"0001437749-26-029175","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774926029175/rdgdoc.xml","form_type":"4"}},{"id":727628,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true}}],"security":"Restricted Stock Unit","published_at":"2026-06-24T14:02:42.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates."}],"balance_after":8000,"derivative":{"underlying":"Ordinary Shares","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001437749-26-021517","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774926021517/rdgdoc.xml","form_type":"4"}},{"id":727627,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true}}],"security":"Stock Option (right ot buy)","published_at":"2026-06-24T14:02:42.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates."}],"balance_after":10000,"derivative":{"exercise_price":34.99,"expiration_date":"2036-06-22","underlying":"Ordinary Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001437749-26-021517","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774926021517/rdgdoc.xml","form_type":"4"}},{"id":761798,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true}}],"security":"Restricted Stock Unit","published_at":"2026-05-27T12:04:51.000Z","date":"2026-05-26","kind":"exercise","planned":false,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"}],"balance_after":2000,"derivative":{"underlying":"Ordinary Shares","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001437749-26-018442","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774926018442/rdgdoc.xml","form_type":"4"}},{"id":761797,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true}}],"security":"ordinary shares","published_at":"2026-05-27T12:04:51.000Z","date":"2026-05-26","kind":"exercise","planned":false,"acquired":true,"shares":2000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001437749-26-018442","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774926018442/rdgdoc.xml","form_type":"4"}},{"id":877285,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true}}],"security":"Restricted Stock Unit","published_at":"2026-02-27T21:44:12.000Z","date":"2025-02-26","kind":"exercise","planned":false,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"}],"balance_after":4000,"derivative":{"underlying":"Ordinary Shares","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001437749-26-006124","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774926006124/rdgdoc.xml","form_type":"4"}},{"id":877284,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true}}],"security":"ordinary shares","published_at":"2026-02-27T21:44:12.000Z","date":"2025-02-26","kind":"exercise","planned":false,"acquired":true,"shares":2000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"}],"balance_after":4000,"source":{"system":"sec-edgar","filing":"0001437749-26-006124","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774926006124/rdgdoc.xml","form_type":"4"}},{"id":937074,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-01-16T22:00:03.000Z","date":"2026-01-10","kind":"exercise","planned":false,"acquired":false,"shares":3430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3430},"source":{"system":"sec-edgar","filing":"0001193125-26-015484","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000119312526015484/ownership.xml","form_type":"4"}},{"id":937073,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-16T22:00:03.000Z","date":"2026-01-10","kind":"exercise","planned":false,"acquired":true,"shares":3430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026."}],"balance_after":3430,"source":{"system":"sec-edgar","filing":"0001193125-26-015484","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000119312526015484/ownership.xml","form_type":"4"}},{"id":985072,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true}}],"security":"Restricted Stock Unit","published_at":"2025-12-01T21:47:46.000Z","date":"2025-11-26","kind":"exercise","planned":false,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"}],"balance_after":6000,"derivative":{"underlying":"Ordinary Shares","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001437749-25-036559","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774925036559/rdgdoc.xml","form_type":"4"}},{"id":985071,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true}}],"security":"ordinary shares","published_at":"2025-12-01T21:47:46.000Z","date":"2025-11-26","kind":"exercise","planned":false,"acquired":true,"shares":2000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"}],"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001437749-25-036559","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774925036559/rdgdoc.xml","form_type":"4"}},{"id":1054536,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true}}],"security":"Restricted Stock Unit","published_at":"2025-08-27T20:39:09.000Z","date":"2025-08-26","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates."}],"balance_after":8000,"derivative":{"underlying":"Ordinary Shares","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001437749-25-027882","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774925027882/rdgdoc.xml","form_type":"4"}},{"id":1054535,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true}}],"security":"Stock Option (right ot buy)","published_at":"2025-08-27T20:39:09.000Z","date":"2025-08-26","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates."}],"balance_after":10000,"derivative":{"exercise_price":19.5,"expiration_date":"2035-08-26","underlying":"Ordinary Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001437749-25-027882","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774925027882/rdgdoc.xml","form_type":"4"}},{"id":1304238,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-01-13T22:30:04.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":3430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the total restricted stock units will vest on January 10, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"100% of the total restricted stock units will vest on January 10, 2026."}],"balance_after":3430,"derivative":{"underlying":"Common Stock","underlying_shares":3430},"source":{"system":"sec-edgar","filing":"0000950170-25-004920","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000095017025004920/ownership.xml","form_type":"4"}},{"id":1304237,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-13T22:30:04.000Z","date":"2035-01-10","kind":"grant","planned":false,"acquired":true,"shares":30870,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 30,870 shares of common stock, which option vests with respect to 100% of the total number of shares on January 10, 2026."}],"balance_after":30870,"derivative":{"exercise_price":4.04,"expiration_date":"2035-01-10","underlying":"Common Stock","underlying_shares":30870},"source":{"system":"sec-edgar","filing":"0000950170-25-004920","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000095017025004920/ownership.xml","form_type":"4"}},{"id":1437865,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true}}],"security":"Stock Option (right ot buy)","published_at":"2024-08-08T13:08:16.000Z","date":"2024-08-06","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates."}],"balance_after":10000,"derivative":{"exercise_price":15.16,"expiration_date":"2034-08-06","underlying":"Ordinary Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001437749-24-025293","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774924025293/rdgdoc.xml","form_type":"4"}},{"id":1767079,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-03T20:19:12.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":150437,"price":1.55,"value":233177.35,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 150,437 shares of Common Stock, which option vests with respect to 75,219 shares on October 2, 2024 and with respect to 75,218 shares on October 2, 2025."}],"balance_after":150437,"derivative":{"exercise_price":1.55,"expiration_date":"2033-10-02","underlying":"Common Stock","underlying_shares":150437},"source":{"system":"sec-edgar","filing":"0001209191-23-051460","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000120919123051460/doc4.xml","form_type":"4"}},{"id":1784653,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true}}],"security":"Stock Option (right ot buy)","published_at":"2023-09-08T19:41:58.000Z","date":"2023-09-07","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option will vest in equal quarterly installments over a period of one year."}],"balance_after":10000,"derivative":{"exercise_price":16.85,"expiration_date":"2033-09-07","underlying":"Ordinary Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001437749-23-025481","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774923025481/rdgdoc.xml","form_type":"4"}},{"id":1821487,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2023-07-28T22:05:31.000Z","date":"2023-07-25","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option vest in equal quarterly installments over 12 months"}],"balance_after":20000,"derivative":{"exercise_price":8.84,"expiration_date":"2033-07-25","underlying":"Ordinary Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001437749-23-021072","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774923021072/rdgdoc.xml","form_type":"4/A","original_submission_date":"2023-07-27"}},{"id":1822162,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2023-07-27T20:30:47.000Z","date":"2023-07-25","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option vest in equal quarterly installments over 12 months"}],"balance_after":20000,"derivative":{"exercise_price":8.9,"expiration_date":"2033-07-25","underlying":"Ordinary Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001437749-23-020905","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774923020905/rdgdoc.xml","form_type":"4"}},{"id":2099926,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-01T09:23:47.000Z","date":"2022-11-30","kind":"disposition_to_issuer","acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":2.17,"expiration_date":"2031-11-30","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001062993-22-023030","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000106299322023030/form4.xml","form_type":"4"}},{"id":2488455,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-12-02T19:53:48.000Z","date":"2021-11-30","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option becomes exercisable for one third of the underlying shares on the first anniversary of the grant date, and thereafter becomes exercisable for the remaining underlying shares, in equal monthly installments over two years, resulting in the option being exercisable for 100% of the underlying shares on the third anniversary of the grant date."}],"balance_after":25000,"derivative":{"exercise_price":2.17,"expiration_date":"2031-11-30","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001062993-21-012070","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000106299321012070/form4.xml","form_type":"4"}},{"id":2765906,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PEO;CEO/Urovant Sciences, Inc."}}],"security":"Stock Appreciation Right (Right to Buy)","published_at":"2021-03-31T16:30:45.000Z","date":"2021-03-29","kind":"disposition_to_issuer","acquired":false,"shares":845732,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon consummation of the Merger, each right to receive an appreciation on Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had a strike price per Common Share that is less than $16.25 was canceled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such appreciation right that is equal to the difference between $16.25 and the strike price per Common Share of such appreciation right, without interest and less any applicable withholding for taxes, as described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":9.16,"expiration_date":"2030-03-22","underlying":"Common Shares","underlying_shares":845732},"source":{"system":"sec-edgar","filing":"0000899243-21-014110","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1734295/000089924321014110/doc4.xml","form_type":"4"}},{"id":2765905,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PEO;CEO/Urovant Sciences, Inc."}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-31T16:30:45.000Z","date":"2021-03-29","kind":"disposition_to_issuer","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":8.78,"expiration_date":"2029-07-09","underlying":"Common Shares","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-21-014110","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1734295/000089924321014110/doc4.xml","form_type":"4"}},{"id":2765904,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PEO;CEO/Urovant Sciences, Inc."}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-31T16:30:45.000Z","date":"2021-03-29","kind":"disposition_to_issuer","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":12.41,"expiration_date":"2029-03-01","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-21-014110","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1734295/000089924321014110/doc4.xml","form_type":"4"}},{"id":2765903,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PEO;CEO/Urovant Sciences, Inc."}}],"security":"Common Shares","published_at":"2021-03-31T16:30:45.000Z","date":"2021-03-29","kind":"disposition_to_issuer","acquired":false,"shares":8385,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the consummation of the Merger, each outstanding common share of the Issuer (\"Common Share\") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-014110","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1734295/000089924321014110/doc4.xml","form_type":"4"}},{"id":2777555,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-19T17:36:41.000Z","date":"2021-03-19","kind":"disposition_to_issuer","acquired":false,"shares":46907,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"exercise_price":1.44,"underlying":"Common Stock","underlying_shares":46907},"source":{"system":"sec-edgar","filing":"0001104659-21-039230","document":"tm219870-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465921039230/tm219870-13_4seq1.xml","form_type":"4"}},{"id":2777554,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-19T17:36:41.000Z","date":"2021-03-19","kind":"disposition_to_issuer","acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an \"Assumed Company Option\") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"exercise_price":2.03,"underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001104659-21-039230","document":"tm219870-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465921039230/tm219870-13_4seq1.xml","form_type":"4"}},{"id":2777553,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-19T17:36:41.000Z","date":"2021-03-19","kind":"disposition_to_issuer","acquired":false,"shares":23453,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\") dated as of December 10, 2020, by and among the Company, Aytu BioScience, Inc. (\"Parent\"), and Neutron Acquisition Sub, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Company (the \"Merger\") effective as of March 19, 2021 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a \"Share\") (excluding any Shares held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 0.1088 (the \"Exchange Ratio\") shares of Common Stock of Parent (the \"Parent Common Stock\"), plus the right, if any, to receive cash in lieu of fractional shares of Parent Common Stock into which such Shares would have been converted (as described in the Merger Agreement)."},{"field":"shares","element":"transactionShares","label":"F3","text":"This number includes 23,453 restricted stock units (each, an \"RSU\") held by the Reporting Person. At the Effective Time, each RSU that was outstanding prior to the Effective Time immediately and automatically ceased to represent a right to acquire shares of Company Common Stock and was assumed by Parent and converted automatically into a restricted stock unit denominated in Parent Common Stock equal to the number of Shares subject to the RSU prior to the Effective Time multiplied by the Exchange Ratio, and any cash in lieu of fractional shares of Parent Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\") dated as of December 10, 2020, by and among the Company, Aytu BioScience, Inc. (\"Parent\"), and Neutron Acquisition Sub, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Company (the \"Merger\") effective as of March 19, 2021 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a \"Share\") (excluding any Shares held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 0.1088 (the \"Exchange Ratio\") shares of Common Stock of Parent (the \"Parent Common Stock\"), plus the right, if any, to receive cash in lieu of fractional shares of Parent Common Stock into which such Shares would have been converted (as described in the Merger Agreement)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-21-039230","document":"tm219870-13_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465921039230/tm219870-13_4seq1.xml","form_type":"4"}},{"id":2909036,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PEO; CEO/Urovant Sciences, Inc"}}],"security":"Common Shares","published_at":"2021-01-13T00:02:40.000Z","date":"2021-01-10","kind":"tax_withholding","acquired":false,"shares":4095,"price":16.11,"value":65970.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock withheld by the Issuer to pay tax withholding obligations of the Reporting Person upon the vesting of restricted stock units previously granted to the Reporting Person."}],"balance_after":8385,"source":{"system":"sec-edgar","filing":"0001209191-21-003314","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1734295/000120919121003314/doc4.xml","form_type":"4"}},{"id":3113327,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-11T20:23:10.000Z","date":"2020-06-10","kind":"grant","acquired":true,"shares":23453,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares of common stock underlying restricted stock unit grants awarded to the Reporting Person. The restricted stock units will vest on the one-year anniversary of June 10, 2020."}],"balance_after":23453,"source":{"system":"sec-edgar","filing":"0001104659-20-072549","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465920072549/a4.xml","form_type":"4"}},{"id":3194919,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PEO;CEO/Urovant Sciences, Inc."}}],"security":"Stock Appreciation Right (Right to Buy)","published_at":"2020-03-25T21:00:21.000Z","date":"2020-03-23","kind":"grant","acquired":true,"shares":845732,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the stock appreciation rights (\"SARs\") shall vest and become exercisable on March 23, 2021; the remaining SARs vest in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The SARs may be settled in cash or in the Issuer's common shares."}],"balance_after":845732,"derivative":{"exercise_price":9.16,"expiration_date":"2030-03-22","underlying":"Common Shares","underlying_shares":845732},"source":{"system":"sec-edgar","filing":"0000899243-20-009409","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1734295/000089924320009409/doc4.xml","form_type":"4"}},{"id":3311368,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2020-01-14T21:09:31.000Z","date":"2020-01-10","kind":"grant","acquired":true,"shares":12480,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units shall vest on January 10, 2021, subject to the Reporting Person providing continuous service to the Issuer through such vesting date."}],"balance_after":12480,"source":{"system":"sec-edgar","filing":"0001209191-20-003287","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1734295/000120919120003287/doc4.xml","form_type":"4"}},{"id":3463381,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-11T17:16:22.000Z","date":"2019-07-09","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest and become exercisable on July 9, 2020, subject to the Reporting Person providing continuous service to the Issuer through such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":8.78,"expiration_date":"2029-07-09","underlying":"Common Shares","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-19-041792","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1734295/000120919119041792/doc4.xml","form_type":"4"}},{"id":3487672,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-17T17:33:51.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":46907,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option vests in equal quarterly installments over a one-year period which began on June 13, 2019."}],"balance_after":46907,"derivative":{"exercise_price":1.44,"expiration_date":"2029-06-13","underlying":"Common Stock","underlying_shares":46907},"source":{"system":"sec-edgar","filing":"0001104659-19-035983","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465919035983/a4.xml","form_type":"4"}},{"id":3561109,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"officer":true,"officer_title":"President & COO,Alkermes, Inc."}}],"security":"Restricted Stock Unit Award","published_at":"2019-04-05T21:10:18.000Z","date":"2019-04-04","kind":"exercise","acquired":false,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the restricted stock unit award vest in four equal annual installments commencing on 4/4/2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Shares subject to the restricted stock unit award vest in four equal annual installments commencing on 4/4/2019."}],"balance_after":18750,"derivative":{"exercise_price":0,"exercise_date":"2019-04-04","underlying":"Ordinary Shares","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001127602-19-014943","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760219014943/form4.xml","form_type":"4"}},{"id":3561108,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"officer":true,"officer_title":"President & COO,Alkermes, Inc."}}],"security":"Ordinary Shares","published_at":"2019-04-05T21:10:18.000Z","date":"2019-04-04","kind":"tax_withholding","acquired":false,"shares":1838,"price":35.89,"value":65965.82,"ownership":{"direct":true},"balance_after":4412,"source":{"system":"sec-edgar","filing":"0001127602-19-014943","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760219014943/form4.xml","form_type":"4"}},{"id":3561107,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"officer":true,"officer_title":"President & COO,Alkermes, Inc."}}],"security":"Ordinary Shares","published_at":"2019-04-05T21:10:18.000Z","date":"2019-04-04","kind":"exercise","acquired":true,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6250,"source":{"system":"sec-edgar","filing":"0001127602-19-014943","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760219014943/form4.xml","form_type":"4"}},{"id":3610315,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-03-06T01:44:49.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest and become exercisable in three equal annual installments beginning on March 1, 2020, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date."}],"balance_after":50000,"derivative":{"exercise_price":12.41,"expiration_date":"2029-03-01","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-19-017192","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1734295/000120919119017192/doc4.xml","form_type":"4"}},{"id":3635178,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"officer":true,"officer_title":"President & COO,Alkermes, Inc."}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-02-25T22:34:07.000Z","date":"2019-02-21","kind":"grant","acquired":true,"shares":157000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares subject to the stock option award vest in four equal annual installments commencing on 2/21/2020."}],"balance_after":157000,"derivative":{"exercise_price":32.57,"exercise_date":"2020-02-21","expiration_date":"2029-02-21","underlying":"Ordinary Shares","underlying_shares":157000},"source":{"system":"sec-edgar","filing":"0001127602-19-008127","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760219008127/form4.xml","form_type":"4"}},{"id":3635177,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"officer":true,"officer_title":"President & COO,Alkermes, Inc."}}],"security":"Restricted Stock Unit Award","published_at":"2019-02-25T22:34:07.000Z","date":"2019-02-21","kind":"grant","acquired":true,"shares":40400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/21/2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/21/2020."}],"balance_after":40400,"derivative":{"exercise_price":0,"exercise_date":"2020-02-21","underlying":"Ordinary Shares","underlying_shares":40400},"source":{"system":"sec-edgar","filing":"0001127602-19-008127","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760219008127/form4.xml","form_type":"4"}},{"id":3682610,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-30T17:37:38.000Z","date":"2019-01-29","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option vests in equal quarterly installments over a two-year period which began on January 29, 2019."}],"balance_after":12500,"derivative":{"exercise_price":2.03,"expiration_date":"2029-01-29","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001104659-19-004506","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465919004506/a4.xml","form_type":"4"}},{"id":3874084,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"officer":true,"officer_title":"President & COO,Alkermes, Inc."}}],"security":"Restricted Stock Unit Award","published_at":"2018-07-03T21:06:01.000Z","date":"2018-04-04","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Late filing due to administrative error."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares subject to the restricted stock unit award vest in four equal annual installments commencing on 4/4/2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares subject to the restricted stock unit award vest in four equal annual installments commencing on 4/4/2019."}],"balance_after":25000,"derivative":{"exercise_price":0,"exercise_date":"2019-04-04","underlying":"Ordinary Shares","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001127602-18-022684","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760218022684/form4.xml","form_type":"4"}},{"id":3874083,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"officer":true,"officer_title":"President & COO,Alkermes, Inc."}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-07-03T21:06:01.000Z","date":"2018-04-04","kind":"grant","acquired":true,"shares":140000,"price":44.16,"value":6182400.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Late filing due to administrative error."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares subject to the stock option award vest in four equal annual installments commencing on 4/4/2019."}],"balance_after":140000,"derivative":{"exercise_price":44.16,"exercise_date":"2019-04-04","expiration_date":"2028-04-04","underlying":"Ordinary Shares","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001127602-18-022684","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760218022684/form4.xml","form_type":"4"}}]}